Curves

Curve Therapeutics is a private biotechnology company based in Southampton, UK, that is pioneering a functional drug discovery platform to address 'undruggable' intracellular targets. The company's proprietary Microcycle® technology enables the discovery of cyclic peptide ligands that can disrupt complex protein-protein interactions within the cellular environment. Curve's internal pipeline is focused on high-value oncology targets, including a lead program targeting dual HIF-1/HIF-2 and a program focused on KRAS mutations. The company has established a significant strategic collaboration with MSD (Merck & Co.) to identify candidates for multiple oncology and neurology targets. In 2024, Curve closed a £40.5 million Series A financing round to advance its lead assets toward clinical development.